玻璃体腔注射康柏西普治疗湿性老年性黄斑变性的临床观察

Clinical Observation of Conbercept Intravitreal Injection Treatment on Wet Age-related Macular Degeneration

目的观察湿性老年性黄斑变性行玻璃体腔注射康柏西普后的疗效。方法将确诊为湿性老年性黄斑变性的患者30例(38眼)给予康柏西普0.5mg(0.05ml)玻璃体腔注射,观察术前、术后1周、2周、1个月的最佳矫正ETDRS视力及黄斑区视网膜中心厚度。结果术后1周、2周及1个月最佳矫正ETDRS视力分别为(45.34±10.75),(49.06±11.28),(52.09±11.92)个字母,均较术前(35.06±13.67)个字母有提高,差异有统计学意义(均P<0.05);术后1周、2周及1个月黄斑区视网膜中心厚度分别为(382.83±90.67)μm,(367.23±63.73)μm,(326.22±58.74)μm,均较术前(480.63±92.97)μm变薄,差异有统计学意义(均P<0.05)。治疗期间未发生严重并发症。结论玻璃体腔注射康柏西普后可减轻湿性老年性黄斑变性患者的黄斑水肿,提高患者视力。

Objective To observe the efficacy of Conbercept intravitreal injection treatment on wet age -related macular degenera-tion.Methods Thirty cases patients（38 eyes）diagnosed with age-related macular degeneration were seclected and injected Conbercep 0.5mg （0.05ml） intravitreal,and the visual acuity and the central macular thinckness of preoperative ,postoperative 1 week,postoperative two weeks and postoperative 1 month were measured with the international standard treatment of early diabetic eye chart （ETDRS）.Results The best corrected ETDRS visual acuity of postoperative 1 week,after two weeks and after 1 month was 45.34 ±10.75,49.06 ±11.28,52.09 ±11.92 （number of letters）,which were all higher than preoperative （35.06 ±13.67 number of letters）,the differences were statistically significant （P〈0.05）.The central macular thinckness of postoperative 1 week,postoperative two weeks and postoperative 1 month was 382.83μm ±90. 67μm,367.23μm ±63.73μm,326.22μm ±58.74μm,which were thinner than preoperative （480.63μm ±92.97μm）,the differences were statistically significant（P〈0.05）,too.No serious complications occurred during treatment .Conclusion Conbercep intravitreal can reduce the macular edema of patients with wet age-related macular degeneration and improve visual acuity .